Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells

Clinical Cancer Research

Volumn 10, Issue 19, 2004, Pages 6466-6475

  Garofalo, Cecilia ^a   Sisci, Diego ^b   Surmacz, Eva ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; LEPTIN; LEPTIN RECEPTOR; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; STAT3 PROTEIN; UBIQUITIN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; METASTASIS; OBESITY; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LEPTIN; LUCIFERASES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROMOTER REGIONS (GENETICS); PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; UBIQUITIN;

EID: 5144229540     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0203     Document Type: Article

References (58)

1. Stephenson GD, Rose DP. Breast cancer and obesity: an update. Nutr Cancer 2003;45:1-16.
2. Rose DP, Gilhooly EM, Nixon DW. Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin [review]. Int J Oncol 2002;21:1285-92.
3. Cleary MP, Maihle NJ. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med 1997;216:28-43.
4. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002;20:1128-43.
5. Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 1994;120:18-25.
6. Klurfeld DM, Lloyd LM, Welch CB, Davis MJ, Tulp OL, Kritchevsky D. Reduction of enhanced mammary carcinogenesis in LA/N-cp (corpulent) rats by energy restriction. Proc Soc Exp Biol Med 1991; 196:381-4.
7. Waxier SH. Obesity and cancer susceptibility in mice. Am J Clin Nutr 1960;8:760-6.
8. Wolff GL, Kodell RL, Cameron AM, Medina D. Accelerated appearance of chemically induced mammary carcinomas in obese yellow (Avy/A) (BALB/c X VY) F1 hybrid mice. J Toxicol Environ Health 1982;10:131-42.
9. Heston WE, Vlahakis G. Genetic obesity and neoplasia. J Natl Cancer Inst (Bethesda) 1962;29:197-209.
10. Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 2000; 143:293-311.
11. Neville MC, McFadden TB, Forsyth I. Hormonal regulation of mammary differentiation and milk secretion. J Mammary Gland Biol Neoplasia 2002;7:49-66.
12. Bonnet M, Delavaud C, Laud K, et al. Mammary leptin synthesis, milk leptin and their putative physiological roles. Reprod Nutr Dev 2002;42:399-413.
13. Brann DW, Wade MF, Dhandapani KM, Mahesh VB, Buchanan CD. Leptin and reproduction. Steroids 2002;67:95-104.
14. Goumenou AG, Matalliotakis IM, Koumantakis GE, Panidis DK. The role of leptin in fertility. Eur J Obstet Gynecol Reprod Biol 2003;106:118-24.
15. Sierra-Honigmann MR, Nat AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998;281:1683-6.
16. Attoub S, Noe V, Pirola L, et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB J 2000;14:2329-33.
17. Tsuchiya T, Shimizu H, Horie T, Mori M. Expression of leptin receptor in lung: leptin as a growth factor. Eur Pharmacol 1999;365: 273-9.
18. Hu X, Juneja SC, Maihle NJ, Cleary MP. Leptin: a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst (Bethesda) 2002;94:1704-11.
19. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC, Pecquery R, Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun 2002;293:622-8.
20. Laud K, Gourdou I, Pessemesse L, Peyrat JP, Djiane J. Identification of leptin receptors in human breast cancer, functional activity in the T47-D breast cancer cell line. Mol Cell Endocrinol 2002;188:219-26.
21. Baratta M, Grolli S, Tamanini C. Effect of leptin in proliferating and differentiated HC11 mouse mammary cells. Regul Pept 2003;113: 101-7.
22. Okumura M, Yamamoto M, Sakuma H, et al. Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-α and PPAR expression. Biochim Biophys Acta 2002;1592:107-16.
23. Tartaglia LA. The leptin receptor. J Biol Chem 1997;272:6093-6.
24. Barr VA, Lane K, Taylor SI. Subcellular localization and internalization of the four human leptin receptor isoforms. J Biol Chem 1999; 274:21416-24.
25. Sweeney G. Leptin signalling. Cell Signalling 2002;14:655-63.
26. Zabeau L, Lavens D, Peelman F, Eyckerman S, Vandekerckhove J, Tavernier J. The ins and outs of leptin receptor activation. FEBS Lett 2003;546:45-50.
27. Bjorbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 1997;272:32686-95.
28. Bjorbaek C, Buchholz RM, Davis SM, et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem 2001;276: 4747-55.
29. Smith-Kirwin SM, O'Connor DM, De Johnston J, Lancey ED, Hassink SG, Funanage VL. Leptin expression in human mammary epithelial cells and breast milk. J Clin Endocrinol Metab 1998;83: 1810-3.
30. Cleary MP, Phillips FC, Getzin SC, et al. Genetically obese MMTV-TGF-α/Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat 2003;77:205-15.
31. O'Brien SN, Welter BH, Price TM. Presence of leptin in breast cell lines and breast tumors. Biochem Biophys Res Commun 1999;259: 695-8.
32. Tessitore L, Vizio B, Jenkins O, et al. Leptin expression in colorectal and breast cancer patients. Int J Mol Med 2000;5:421-6.
33. Petridou E, Papadiamantis Y, Markopoulos C, Spanos E, Dessypris N, Trichopoulos D. Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control 2000;11:383-8.
34. Mantzoros CS, Bolhke K, Moschos S, Cramer DW. Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. Int J Cancer 1999;80:523-6.
35. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86:225-30.
36. Magoffin DA, Weitsman SR, Aagarwal SK, Jakimiuk AJ. Leptin regulation of aromatase activity in adipose stromal cells from regularly cycling women. Ginekol Pol 1999;70:1-7.
37. Kitawaki J, Kusuki I, Koshiba H, Tsukamoto K, Honjo H. Leptin directly stimulates aromatase activity in human luteinized granulose cells. Mol Hum Reprod 1999;5:708-13.
38. Catalano S, Marsico S, Giordano C, et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem 2003;278:28668-76.
39. Spicer LJ, Francisco CC. The adipose obese gene product, leptin: evidence of a direct inhibitory role in ovarian function. Endocrinology 1997;138:3374-9.
40. Ghizzoni L, Barreca A, Mastorakos G, et al. Leptin inhibits steroid biosynthesis by human granulosa-lutein cells. Horm Metab Res 2001; 33:323-8.
41. Machinal-Quelin F, Dieudonne MN, Pecquery R, Leneveu MC, Giudicelli Y. Direct in vitro effects of androgens and estrogens on ob gene expression and leptin secretion in human adipose tissue. Endocrine 2002;18:179-84.
42. Bennett PA, Lindell K, Karlsson C, Robinson IC, Carlsson LM, Carlsson B. Differential expression and regulation of leptin receptor isoforms in the rat brain: effects of fasting and oestrogen. Neuroendocrinology 1998;67:29-36.
43. Lindell K, Bennett PA, Itoh Y, Robinson IC, Carlsson LM, Carlsson B. Leptin receptor 5′untranslated regions in the rat: relative abundance, genomic organization and relation to putative response elements. Mol Cell Endocrinol 2001;172:37-45.
44. Bundred N, Howell A. Fulvestrant (Faslodex): current status in the therapy of breast cancer. Expert Rev Anticancer Ther 2002;2:151-60.
45. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 2000; 89:817-25.
46. Marsaud V, Gougelet A, Maillard S, Renoir JM. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor α (ERα), differentially affect ERα extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol Endocrinol 2003;17:2013-27.
47. Fan M, Bigsby RM, Nephew KP. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-α and essential for the antiproliferative activity of ICI 182,780 in ERα-positive breast cancer cells. Mol Endocrinol 2003;17:356-65.
48. Salerno M, Sisci D, Mauro L, Guvakova M, Ando S, Surmacz E, Insulin receptor substrate 1 (IRS-1) is a target of a pure antiestrogen ICI 182,780 in breast cancer cells. Int J Cancer 1999;81:299-304.
49. Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGFIR) signaling pathway in breast cancer cells. Cancer Res 1997;57:2606-10.
50. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000;103:843-52.
51. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992;89:4037-41.
52. Fuchs SY. The role of ubiquitin-proteasome pathway in oncogenic signaling. Cancer Biol Ther 2002;1:337-41.
53. Bray GA. The underlying basis for obesity, relationship to cancer. J Nutr 2002;132(Suppl):S3451-5.
54. Sinha MK, Opentanova I, Ohannesian JP, et al. Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. J Clin Investig 1996;98: 1277-82.
55. Van Dielen FMH, van'T Veer C, Buurman WA, Greve JWM. Leptin and soluble leptin receptor levels in obese and weight-losing individuals. J Clin Endocrinol Metab 2002;87:1708-16.
56. Catalano S, Mauro L, Marsico S, et al. Leptin induces, via ERK1/2 signal, functional activation of estrogen receptor α in MCF-7 cells. J Biol Chem 2004;279:19908-15.
57. Surmacz E, Burgaud J-L. Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clin Cancer Res 1995;1:1429-36.
58. Bartucci M, Morelli C, Mauro L, Ando' S, Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDAMB-231 breast cancer cells. Cancer Res 2001;61:6747-54.